Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer. Cancer Chemother Pharmacol. 2021 May; 87(5):673-679.
View in:
PubMed
Lessons from the front: designing and implementing clinical pathways by and for clinicians. Am J Manag Care. 2020 02; 26(2 Spec No.):SP57-SP59.
View in:
PubMed
A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer. Ann Oncol. 2013 Jul; 24(7):1841-1847.
View in:
PubMed
Developing a Novel Model to Improve Research and care for Cancer Survivors: a Feasibility Study. J Cancer Educ. 2019 04; 34(2):229-233.
View in:
PubMed
Clinical Impact of Second Opinion Radiology Consultation for Patients With Breast Cancer. J Am Coll Radiol. 2019 Jun; 16(6):814-823.
View in:
PubMed
Age and the Risk of Paclitaxel-Induced Neuropathy in Women with Early-Stage Breast Cancer (Alliance A151411): Results from 1,881 Patients from Cancer and Leukemia Group B (CALGB) 40101. Oncologist. 2019 05; 24(5):617-623.
View in:
PubMed
Impact of Genomic Assay Testing and Clinical Factors on Chemotherapy Use After Implementation of Standardized Testing Criteria. Oncologist. 2019 05; 24(5):595-602.
View in:
PubMed
Surgeon Variability and Factors Predicting for Reoperation Following Breast-Conserving Surgery. Ann Surg Oncol. 2018 Sep; 25(9):2573-2578.
View in:
PubMed
Implementation of Surgeon-Initiated Gene Expression Profile Testing (Onco type DX) Among Patients With Early-Stage Breast Cancer to Reduce Delays in Chemotherapy Initiation. J Oncol Pract. 2017 09; 13(9):e815-e820.
View in:
PubMed
Factors Associated With Delays in Chemotherapy Initiation Among Patients With Breast Cancer at a Comprehensive Cancer Center. J Natl Compr Canc Netw. 2016 12; 14(12):1519-1526.
View in:
PubMed
Teamwork and Electronic Health Record Implementation: A Case Study of Preserving Effective Communication and Mutual Trust in a Changing Environment. J Oncol Pract. 2016 11; 12(11):1075-1083.
View in:
PubMed
Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study. Breast. 2016 Dec; 30:136-140.
View in:
PubMed
Implementation of a Breast/Reconstruction Surgery Coordinator to Reduce Preoperative Delays for Patients Undergoing Mastectomy With Immediate Reconstruction. J Oncol Pract. 2016 Mar; 12(3):e338-43.
View in:
PubMed
Variation in Additional Breast Imaging Orders and Impact on Surgical Wait Times at a Comprehensive Cancer Center. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S428-34.
View in:
PubMed
The Influence of Radiology Image Consultation in the Surgical Management of Breast Cancer Patients. Ann Surg Oncol. 2015 Oct; 22(10):3383-8.
View in:
PubMed
Using real time locating systems (RTLS) to redesign room allocation in an ambulatory cancer care setting. J Clin Oncol. 2014 Oct 20; 32(30_suppl):157.
View in:
PubMed
Characteristics of emergency department visits among non-admitted oncology patients. J Clin Oncol. 2014 Oct 20; 32(30_suppl):37.
View in:
PubMed
Standardizing coordination between surgical oncology and reconstructive surgery for breast cancer patients undergoing mastectomy with immediate reconstruction. J Clin Oncol. 2014 Oct 20; 32(30_suppl):110.
View in:
PubMed
Understanding process-of-care delays in surgical treatment of breast cancer at a comprehensive cancer center. Breast Cancer Res Treat. 2014 Nov; 148(1):125-33.
View in:
PubMed
Use of potassium concentrations as a quality-of-service metric for phlebotomists detects systematic preanalytical biases and facilitates their correction. Clin Chem. 2014 Nov; 60(11):1453-5.
View in:
PubMed
Measuring opportunities to improve timeliness of breast cancer care at Dana-Farber/Brigham and Women's Cancer Center. J Natl Compr Canc Netw. 2014 Feb; 12 Suppl 1:S5-9.
View in:
PubMed
Reducing breast cancer chemotherapy treatment delays by improving the transition from surgical to medical oncology. J Clin Oncol. 2013 Nov; 31(31_suppl):51.
View in:
PubMed
Disseminating team training across an academic cancer center and community-based satellites. J Clin Oncol. 2013 Nov; 31(31_suppl):188.
View in:
PubMed
A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer. Ann Oncol. 2013 Jul; 24(7):1841-1847.
View in:
PubMed
High performance teamwork training and systems redesign in outpatient oncology. BMJ Qual Saf. 2013 May; 22(5):405-13.
View in:
PubMed
Team training in adult oncology. J Clin Oncol. 2012 Dec; 30(34_suppl):27.
View in:
PubMed
Integrating value assessment into discussions about the price of cancer drugs. Mayo Clin Proc. 2012 Oct; 87(10):932-4.
View in:
PubMed
Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials. Support Care Cancer. 2012 Nov; 20(11):2661-8.
View in:
PubMed
Long-term outcomes after neoadjuvant trastuzumab and chemotherapy for HER2+ breast cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):e11074.
View in:
PubMed
Will we be able to care for cancer patients in the future? Oncology (Williston Park). 2010 Dec; 24(14):1343-8.
View in:
PubMed
Models of multidisciplinary cancer care: physician and patient perceptions in a comprehensive cancer center. J Oncol Pract. 2010 Nov; 6(6):283-8.
View in:
PubMed
Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer. Int J Clin Oncol. 2010 Aug; 15(4):390-8.
View in:
PubMed
Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer. Clin Breast Cancer. 2008 Jun; 8(3):234-41.
View in:
PubMed
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol. 2007 Aug 10; 25(23):3399-406.
View in:
PubMed
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol. 2007 Aug 10; 25(23):3415-20.
View in:
PubMed
Phase I/II trial in patients with metastatic breast cancer (MBC) previously treated with a taxane and an anthracycline: Final safety data. J Clin Oncol. 2006 Jun 20; 24(18_suppl):10528.
View in:
PubMed
Phase I trial of liposomal doxorubicin and ZD 1839 in patients with refractory gynecological malignancies or metastatic breast cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5085.
View in:
PubMed
Manageable safety profile in patients with taxane-resistant metastatic breast cancer (MBC) treated with ixabepilone: Final report. J Clin Oncol. 2006 Jun 20; 24(18_suppl):10587.
View in:
PubMed
Final efficacy results of a phase I/II trial of ixabepilone in combination with capecitabine in patients with metastatic breast cancer (MBC) previously treated with a taxane and an anthracycline. J Clin Oncol. 2006 Jun 20; 24(18_suppl):10511.
View in:
PubMed
Effects of a music therapy intervention on quality of life and distress in women with metastatic breast cancer. J Soc Integr Oncol. 2006; 4(3):116-24.
View in:
PubMed
Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol. 2005 Nov 20; 23(33):8340-7.
View in:
PubMed
Assessment of a dietary questionnaire in cancer patients receiving cytotoxic chemotherapy. J Clin Oncol. 2005 Nov 20; 23(33):8453-60.
View in:
PubMed
Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer. Int J Radiat Oncol Biol Phys. 2006 Feb 01; 64(2):496-504.
View in:
PubMed
Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol. 2005 Oct 01; 23(28):6919-30.
View in:
PubMed
Adjuvant ovarian suppression versus chemotherapy for premenopausal, hormone-responsive breast cancer: quality of life and efficacy tradeoffs. Breast Cancer Res Treat. 2005 Sep; 93(1):25-34.
View in:
PubMed
[Advances in sentinel node biopsy for breast cancer]. Gan To Kagaku Ryoho. 2004 Oct; 31(10):1601-7.
View in:
PubMed
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol. 2003 Aug 01; 21(15):2889-95.
View in:
PubMed
Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003 Jun 15; 97(12):2972-7.
View in:
PubMed
Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol. 2003 Jan 01; 21(1):46-53.
View in:
PubMed
Lumping versus splitting: the splitters take this round. J Clin Oncol. 2002 Sep 01; 20(17):3576-7.
View in:
PubMed
Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies. Cancer Chemother Pharmacol. 2001 Nov; 48(5):347-55.
View in:
PubMed
New cytotoxic agents and schedules for advanced breast cancer. Semin Oncol. 2001 Aug; 28(4):344-58.
View in:
PubMed
Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001 May 15; 19(10):2722-30.
View in:
PubMed
Quality of life issues among women undergoing high-dose chemotherapy for breast cancer. Breast Dis. 2001; 14:41-50.
View in:
PubMed
Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol. 2000 Mar; 18(6):1212-9.
View in:
PubMed
Double high-dose chemotherapy with stem cell rescue (HD-SCR) in patients with breast cancer - effect of sequence. Cancer Chemother Pharmacol. 2000; 45(3):239-46.
View in:
PubMed
Current perspectives for treatment of breast cancer. Breast Cancer. 2000; 7(4):380-8.
View in:
PubMed
The interval between courses of high-dose chemotherapy with stem cell rescue: therapeutic hypotheses. Bone Marrow Transplant. 1999 Nov; 24(9):939-45.
View in:
PubMed
Oral 5-FU analogues in the treatment of breast cancer. Oncology (Williston Park). 1998 Oct; 12(10 Suppl 7):39-43.
View in:
PubMed
A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors. Cancer. 1998 Feb 01; 82(3):561-6.
View in:
PubMed
The presence of membrane-bound stem cell factor on highly immature nonmetachromatic mast cells in the peripheral blood of a patient with aggressive systemic mastocytosis. J Allergy Clin Immunol. 1996 Oct; 98(4):831-40.
View in:
PubMed